Literature DB >> 27005959

Dimethyloxalylglycine may be enhance the capacity of neural-like cells in treatment of Alzheimer disease.

Fahimeh Ghasemi Moravej1, Mehrangiz Vahabian2, Sara Soleimani Asl1,3.   

Abstract

Although using differentiated stem cells is the best proposed option for the treatment of Alzheimer disease (AD), an efficient differentiation and cell therapy require enhanced cell survival and homing and decreased apoptosis. It seems that hypoxia preconditioning via Dimethyloxalylglycine (DMOG) may increase the capacity of MSC to induce neural like stem cells (NSCs). Furthermore, it can likely improve the viability of NSCs when transplanted into the brain of AD rats.
© 2016 International Federation for Cell Biology.

Entities:  

Keywords:  Alzheimer disease; DMOG; cell therapy

Mesh:

Substances:

Year:  2016        PMID: 27005959     DOI: 10.1002/cbin.10605

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  1 in total

1.  Enhanced angiogenic activity of dimethyloxalylglycine-treated canine adipose tissue-derived mesenchymal stem cells.

Authors:  Sang-Min Kim; Qiang Li; Ju-Hyun An; Hyung-Kyu Chae; Ji-In Yang; Min-Ok Ryu; Aryung Nam; Woo-Jin Song; Hwa-Young Youn
Journal:  J Vet Med Sci       Date:  2019-10-02       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.